Physician profile
Paul C DO
NPI 1942326269
$3,736.86
in general payments reported to CMS, 2019-2025
22 companies · $951 in 2025
The $951 reported for 2025 was more than what 87% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $147 · 2021: $300 · 2022: $465 · 2023: $808 · 2024: $652 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.78 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.59 | 2019-2025 | Creon |
| Astrazeneca Pharmaceuticals LP | $691.05 | 2019-2025 | Tezspire, Fasenra |
| Digestive Care, INC. | $417.70 | 2023-2025 | Pertzye |
| Mylan Specialty L.P. | $248.25 | 2022-2024 | Tobi Podhaler |
| Baxter Healthcare | $237.25 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $221.91 | 2022-2025 | Tezspire |
| Vertex Pharmaceuticals Incorporated | $207.71 | 2020-2025 | Trikafta |
| Philips North America LLC | $156.40 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Sobi, INC | $127.79 | 2020-2024 | |
| Biogen, INC. | $125.00 | 2019 | |
| Ucb, INC. | $81.44 | 2022-2023 | Briviact, Fintepla |
| Chiesi USA, INC. | $63.71 | 2022 | |
| Genentech USA, INC. | $54.70 | 2022-2024 | Evrysdi |
| Pharming Healthcare, INC. | $39.47 | 2022-2023 | Ruconest |
| E.R. Squibb & Sons, L.L.C. | $29.07 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $26.58 | 2024 | Livmarli |
| Harmony Biosciences LLC | $21.66 | 2024 | |
| Genzyme Corporation | $19.54 | 2019 | |
| Neurelis, INC. | $18.47 | 2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $18.29 | 2022 | |
| Covis Pharma Gmbh | $15.36 | 2022 | |
| Alcresta Therapeutics, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.